Eiko Nagata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eiko Nagata has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Akio Hakamata
Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan; Fujimi Children's Clinic, Iwata, Japan
2 shared publicationsEisaku Okada
Division of Community Health and Preventive Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
2 shared publicationsHiroshi Watanabe
Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan
2 shared publicationsKazuo Umemura
Center for Clinical Research, Hamamatsu University Hospital, Hamamatsu, Japan; Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Japan
2 shared publicationsKeiichi Odagiri
Center for Clinical Research, Hamamatsu University Hospital, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan
2 shared publicationsMitsuhiro Nishida
Department of Pediatrics, Hamamatsu Medical Center, Hamamatsu, Japan
2 shared publications
Latest Publications
- Open Access
- 26 March 2022
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 149 (2) , 60-65
Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study
- 26 March 2022
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 149 (2) , 60-65
Open AccessEfficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study
- Open Access
- 19 July 2021
- Published by Springer Nature in Research Square
An Open-Label Single-Arm Clinical Trial of Propranolol Cream in Infantile Hemangioma
Infantile hemangioma (IH) is a common tumor in infants that gradually resolves and is often followed up for observation. However, for cosmetic reasons, parents often opt for treatment. Oral propranolol, the first-line therapy for IH, shows several side effects, including hypotension, bradycardia, and hypoglycemia. No clinical studies on topical propranolol have been conducted using standardized procedures. We evaluated the efficacy and safety of topical propranolol in patients with IH. This multicenter, open-label phase II study was conducted from June 2019 to December 2020 and involved 8 Japanese infants aged 35–150 days with proliferating IH. Patients were treated with 5% propranolol cream twice daily. We examined the efficacy rate based on central evaluation (complete or near-complete healing of the target hemangioma) at weeks 24 and 12, respectively, compared to baseline values. The efficacy rate at week 24 was 68.8% (95% confidence interval: 44.1–85.9%). The surface area, maximum diameter, and color intensity of the target IH decreased over time. Adverse event and drug-related adverse event rates were 87.5% and 0%, respectively. Propranolol cream (5%) is effective and safe in Japanese patients with IH and may be considered a first-choice treatment for small and superficial IHs in cosmetically problematic areas.Trial registration numberThe trial is registered at the Japan Registry of Clinical Trials (jRCTs 041190041).Full date of first registration: 11/06/2019Web link: https://jrct.niph.go.jp/en-latest-detail/jRCTs041190041
- 19 July 2021
- Published by Springer Nature in Research Square
Open AccessAn Open-Label Single-Arm Clinical Trial of Propranolol Cream in Infantile Hemangioma
Infantile hemangioma (IH) is a common tumor in infants that gradually resolves and is often followed up for observation. However, for cosmetic reasons, parents often opt for treatment. Oral propranolol, the first-line therapy for IH, shows several side effects, including hypotension, bradycardia, and hypoglycemia. No clinical studies on topical propranolol have been conducted using standardized procedures. We evaluated the efficacy and safety of topical propranolol in patients with IH. This multicenter, open-label phase II study was conducted from June 2019 to December 2020 and involved 8 Japanese infants aged 35–150 days with proliferating IH. Patients were treated with 5% propranolol cream twice daily. We examined the efficacy rate based on central evaluation (complete or near-complete healing of the target hemangioma) at weeks 24 and 12, respectively, compared to baseline values. The efficacy rate at week 24 was 68.8% (95% confidence interval: 44.1–85.9%). The surface area, maximum diameter, and color intensity of the target IH decreased over time. Adverse event and drug-related adverse event rates were 87.5% and 0%, respectively. Propranolol cream (5%) is effective and safe in Japanese patients with IH and may be considered a first-choice treatment for small and superficial IHs in cosmetically problematic areas.Trial registration numberThe trial is registered at the Japan Registry of Clinical Trials (jRCTs 041190041).Full date of first registration: 11/06/2019Web link: https://jrct.niph.go.jp/en-latest-detail/jRCTs041190041
- Open Access
Comparison of delivery catheter-based and stylet-based right ventricular lead placement at the right ventricular septum under fluoroscopic guidance judged by cardiac CT (Mt. FUJI): a study protocol for the Mt. FUJI randomised controlled trial
Introduction Pacing-induced cardiomyopathy occasionally occurs in patients undergoing pacemaker implantation. Although compared with right ventricular (RV) apical pacing, RV septal pacing can attenuate left ventricular dyssynchrony; the success rate of lead placement on the RV septum using the stylet system is low. Additionally, no randomised controlled trial has addressed the issue regarding the accuracy of RV lead placement on the RV septum using the stylet and delivery catheter systems. This study hypothesises that a newly available delivery catheter system can improve the accuracy of RV lead placement on the RV septum. Methods and analysis In a multicentre, prospective, randomised, single-blind, controlled trial, 70 patients with pacemaker indication owing to atrioventricular block will be randomised to either the delivery catheter or stylet group before the pacemaker implantation procedure. The position of the RV lead tip will be assessed using ECG-gated cardiac CT in all patients within 4 weeks after pacemaker implantation. Lead tip positions are classified into three groups: (1) RV septum, (2) anterior/posterior edge of the RV septal wall and (3) RV free wall. The primary endpoint will be the success rate of RV lead tip placement on the RV septum, which will be evaluated using cardiac CT. Ethics and dissemination This study will be conducted according to the stipulations of the Helsinki Declaration and the institutional review board of Hamamatsu University School of Medicine. The results of the study will be disseminated at several research conferences and will be published in peer-reviewed journals. Trial registration number jRCTs042200014; Pre-results.
Open AccessComparison of delivery catheter-based and stylet-based right ventricular lead placement at the right ventricular septum under fluoroscopic guidance judged by cardiac CT (Mt. FUJI): a study protocol for the Mt. FUJI randomised controlled trial
Introduction Pacing-induced cardiomyopathy occasionally occurs in patients undergoing pacemaker implantation. Although compared with right ventricular (RV) apical pacing, RV septal pacing can attenuate left ventricular dyssynchrony; the success rate of lead placement on the RV septum using the stylet system is low. Additionally, no randomised controlled trial has addressed the issue regarding the accuracy of RV lead placement on the RV septum using the stylet and delivery catheter systems. This study hypothesises that a newly available delivery catheter system can improve the accuracy of RV lead placement on the RV septum. Methods and analysis In a multicentre, prospective, randomised, single-blind, controlled trial, 70 patients with pacemaker indication owing to atrioventricular block will be randomised to either the delivery catheter or stylet group before the pacemaker implantation procedure. The position of the RV lead tip will be assessed using ECG-gated cardiac CT in all patients within 4 weeks after pacemaker implantation. Lead tip positions are classified into three groups: (1) RV septum, (2) anterior/posterior edge of the RV septal wall and (3) RV free wall. The primary endpoint will be the success rate of RV lead tip placement on the RV septum, which will be evaluated using cardiac CT. Ethics and dissemination This study will be conducted according to the stipulations of the Helsinki Declaration and the institutional review board of Hamamatsu University School of Medicine. The results of the study will be disseminated at several research conferences and will be published in peer-reviewed journals. Trial registration number jRCTs042200014; Pre-results.